GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint
By Michael Susin GSK PLC said Monday that its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn’t meet its primary endpoint of progression-free…
Read more GSK Says Dreamm-3 Phase 3 Study For Blenrep Didn’t Meet Primary Endpoint